Lo.Li. Pharma
Lo.Li. Pharma S.r.l. is a privately held Italian pharmaceutical company headquartered in Rome that develops and commercializes proprietary dietary supplements and medical devices in women's health, fertility, endocrinology, urology, and respiratory care, distributed in over 70 countries via medical representatives and partner networks.
- Company typePrivate
- Founded2002
- HeadquartersRome, Italy
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lo.Li. Pharma does
Lo.Li. Pharma S.r.l. is an Italian pharmaceutical company headquartered in Rome that develops and commercializes dietary supplements (integratori alimentari) and medical devices (dispositivi medici). The company was founded in 2002 and operates primarily in women's health (obstetrics, gynecology, fertility), with extensions into endocrinology, andrology, urology, and — following the January 2025 merger with Farmares — respiratory health. Its core technology centers on proprietary inositol-based formulations (myo-inositol and D-chiro-inositol in a 40:1 physiological ratio) combined with alpha-lattoalbumina for enhanced bioavailability, applied to indications including PCOS, fertility support, fibroid management, breast density, and iron absorption. The product portfolio includes the Inofolic line (Inofolic HP, Inofolic Combi HP and variants), eight proprietary gynecological medical devices, and the 15 products plus an MDR-certified respiratory dossier added through the Farmares merger.
The business model is B2B-distributed through a field force. In Italy, sales run through a network of 70+ scientific/medical representatives (informatori scientifici) operating via dedicated portals (My Cura, My Nova, HCPS) that handle physician registration and product information. Internationally, Lo.Li. Pharma International — founded in 2012 — selects and supports country-level commercial partners, with a direct subsidiary established in Madrid (Lo.Li. Pharma International España) for the Iberian market. End demand is generated through healthcare-professional recommendation (gynecologists, endocrinologists, urologists, andrologists) supported by disease-awareness campaigns (Noi PCOS, Sottovoce thyroid initiative, Più Prevenzione Meno HPV, Il Mio Fibroma Podcast, Salute Senologica) and patient tools such as the Free Androgen Index (FAI) Calculator.
Pricing is not publicly disclosed and operates through standard pharma channels: prescription-driven and HCP-recommended supplements and Class I/II medical devices. The company is privately held under founder/Managing Director Patrizia Logoteta with no evidence of external private equity, venture capital, or public shareholders; revenue figures are not disclosed. Recognition includes the Le Fonti Awards (2021), Life Science Excellence Awards (2022), Great Place to Work Italia certification (2022), and the Gran Premio Internazionale di Venezia Leone d'Oro (2017). Inofolic HP holds a first-in-category Lactose Free certification in Italy, Europe and internationally.
Lo.Li. Pharma firmographics
Firmographics- Name
- Lo.Li. Pharma
- Legal name
- Lo. Li. Pharma S.r.l.
- Website
- https://lolipharma.it
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lo.Li. Pharma S.r.l. is a privately held Italian pharmaceutical company headquartered in Rome that develops and commercializes proprietary dietary supplements and medical devices in women's health, fertility, endocrinology, urology, and respiratory care, distributed in over 70 countries via medical representatives and partner networks.
- Ownership category
- akta.pro rank
Lo.Li. Pharma industry classification
Industry- Product category
- Pharmaceutical Dietary Supplements and Medical Devices
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK)
Keywords
Where Lo.Li. Pharma is headquartered
LocationHeadquarters
- HQ city
- Rome
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Lo.Li. Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- Dietary Supplements (Integratori Alimentari): Sale of dietary supplements including Inofolic, Inofolic HP, Inofolic Combi HP, and other formulations targeting fertility, PCOS, menopause, and general women's health.
- Medical Devices (Dispositivi Medici): Sale of medical devices in gynecological, urological, and respiratory categories. Portfolio includes 8 gynecological devices owned by Lo.Li. Pharma plus 15 products from Farmares merger.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Lo.Li. Pharma product offering
Product offeringCore offering
Lo.Li. Pharma develops, manufactures, and commercializes dietary supplements (integratori alimentari) and medical devices (dispositivi medici) primarily for obstetrics, gynecology, endocrinology, andrology, urology, and respiratory health. Flagship offerings are inositol-based formulations (myo-inositol plus D-chiro-inositol, often with alpha-lattoalbumina and folic acid) marketed under the Inofolic brand for female fertility, PCOS, menopause, and breast health, alongside a portfolio of gynecological medical devices and an MDR-certified respiratory device dossier acquired via the 2025 FARMARES merger.
Product overview
Lo.Li. Pharma is an Italian company based in Rome developing and commercializing Medical Devices and Dietary Supplements. The core product portfolio centers on Inofolic HP and Inofolic Combi HP supplements containing myo-inositol, D-chiro-inositol, alfa-lactoalbumina and folic acid for female fertility and gynecological conditions. Following the January 2025 merger with FARMARES, the portfolio expanded to include 15 additional medical devices and dietary supplements plus a respiratory dossier. The company operates internationally through Lo.Li.Pharma International (established 2012) with distribution in over 70 countries. Therapeutic areas include female fertility, gynecology/obstetrics, andrology/male fertility, endocrinology, urology, and respiratory. The product range covers both INTEGRATORI ALIMENTARI (dietary supplements) and DISPOSITIVI MEDICI (medical devices).
Differentiator
Problem solved
Functional benefit
Brands
- Inofolic: Line of dietary supplements based on myo-inositol and D-chiro-inositol for fertility support
- Inositoli
- Zyxelle
- Noi PCOS
- FAI la differenza
- Salupharma
- My Loli
- Linea Cura
- Linea Nova
Products and services
- Inofolic HP Dietary supplement (integratore alimentare) based on myo-inositol, D-chiro-inositol, alfa-lactoalbumina and folic acid, positioned as the first certified lactose-free food supplement in Italy/Europe/internationally. Targeted at physicians (gynecologists, endocrinologists, fertility specialists) and their patients for fertility support, PCOS management, and related gynecological indications.
- Inofolic Combi HP Softgel capsule dietary supplement containing myo-inositol, D-chiro-inositol, alfa-lattoalbumina and folic acid. Marketed as the evolved version of Inofolic Combi with improved performance due to alfa-lattoalbumina's role in enhancing intestinal absorption of inositols. Targeted at fertility specialists and OB-GYNs prescribing for female fertility and PCOS.
- FAI (Free Androgen Index) Calculator Online digital calculator tool for the Free Androgen Index, designed to support healthcare professionals (and patients) in evaluating and monitoring androgen-related clinical parameters in conditions like PCOS, branded under the 'FAI la differenza!' initiative.
Quantifiable outcome
- Products distributed in over 70 countries worldwide
- +1 more outcomes
Companies that use Lo.Li. Pharma
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles1 record
Lo.Li. Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Lo.Li. Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Bone HealthcoreEditorial and non-conditional collaboration with Bone Health portal starting September 2025. Focus on evidence-based bone health content, particularly osteopenia and osteoporosis. Platform serves as reference for specialist physicians, researchers, and healthcare operators with expert-validated content.
- FarmarescoreMerger by incorporation effective January 2, 2025. Farmares was already a controlled subsidiary. Merger integrates 15 medical devices and dietary supplements plus MDR-certified respiratory device dossier into Lo.Li. Pharma portfolio.
- Associazione Italiana Latto-Intolleranti Onlus (AILI)minorCollaboration with Italian lactose intolerance association for certification of Inofolic HP as first lactose-free certified dietary supplement in Italy, Europe, and internationally.
- Ellefree srlminorPartner in lactose-free certification process for Inofolic HP supplement, enabling international certification.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Lo.Li. Pharma competitors and assessment
Company assessmentBroad incumbents
- Sigma-Tau (now part of Alfasigma): Italian specialty pharma group with historic strength in gynecology, endocrinology, and rare disease. Comparable as a domestic pharma incumbent with overlapping specialty franchises and an Italy-rooted HCP sales model.
- Angelini Pharma: Major privately-held Italian pharma group active across women's health, CNS, and consumer health. Comparable as a larger domestic pharma incumbent with overlapping channels into Italian gynecologists and reproductive health HCPs.
- Italfarmaco: Established Italian pharmaceutical group with a women's health, gynecology, and specialty pharma portfolio. Comparable as a larger Italian incumbent operating in overlapping therapeutic areas (gynecology, fertility, endocrinology) with a broader brand and geographic footprint.
- Menarini Group: Italy's largest pharmaceutical company by revenue, with a broad women's health and specialty pharma portfolio. Comparable as a scale Italian pharma incumbent with similar HCP-driven commercialization models and overlapping therapeutic breadth.
- Shionogi (Women's Health unit, ex-Theramex Europe): Global pharma with a dedicated women's health franchise (Theramex) covering fertility, contraception, and menopause in Europe. Comparable as a larger incumbent competing for the same Italian gynecologist and fertility specialist mindshare.
Emerging players
- Named Sport / Named S.p.A. Italian nutraceutical and food supplement company targeting women's health, fertility, and wellness use cases. Comparable as a similarly sized Italian supplement player competing for the same HCP-driven women's health channels and patient segments.
- Metagenics Italia: European medical-grade nutrition and supplement brand with a practitioner-only distribution model. Comparable as a competitor using scientific-evidence positioning and HCP-only channels to sell premium women's health and metabolic supplements.
Regional players
- Effik Italia: European women's health pharma company with gynecology, fertility, and contraceptive portfolio, active in Italy through a dedicated affiliate. Comparable as a regional peer operating in the same gynecology and reproductive health prescribing environment.
Direct peers
- Lo.Li. Pharma International: The wholly-owned international distribution arm of Lo.Li. Pharma, selling the same Inofolic and dietary supplement portfolio through commercial partners in 70+ countries. Relevant as the international commercial vehicle for the parent's product line, useful for benchmarking international channel economics.
- Farmares: Pre-merger subsidiary (now merged into Lo.Li. Pharma as of January 2025) operating 15 medical devices and dietary supplements plus an MDR-certified respiratory dossier. Directly comparable as a same-therapeutic-area Italian medical-device and supplement manufacturer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Lo.Li. Pharma social profiles
Digital presenceLo.Li. Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lo.Li. Pharma leadership team
Management profileNumber of profiles
Profiles1 record
Lo.Li. Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Lo.Li. Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lo.Li. Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lo.Li. Pharma
What does Lo.Li. Pharma do?
Lo.Li. Pharma develops, manufactures, and commercializes dietary supplements (integratori alimentari) and medical devices (dispositivi medici) primarily for obstetrics, gynecology, endocrinology, andrology, urology, and respiratory health. Flagship offerings are inositol-based formulations (myo-inositol plus D-chiro-inositol, often with alpha-lattoalbumina and folic acid) marketed under the Inofolic brand for female fertility, PCOS, menopause, and breast health, alongside a portfolio of gynecological medical devices and an MDR-certified respiratory device dossier acquired via the 2025 FARMARES merger.
Is Lo.Li. Pharma a public or private company?
Lo.Li. Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lo.Li. Pharma founded?
Lo.Li. Pharma was founded in 2002. It employs 11 to 50 people.
Where is Lo.Li. Pharma based?
Lo.Li. Pharma is headquartered in Rome, Italy, in the Europe region.
How does Lo.Li. Pharma make money?
Two revenue lines are on record. Dietary Supplements (Integratori Alimentari) is the primary driver. The others are medical Devices (Dispositivi Medici).
Who are Lo.Li. Pharma's main competitors?
Broad incumbents on record are Sigma-Tau (now part of Alfasigma), Angelini Pharma, Italfarmaco, Menarini Group and Shionogi (Women's Health unit, ex-Theramex Europe). Emerging players are Named Sport / Named S.p.A. and Metagenics Italia. Effik Italia is listed as a regional player. Direct peers are Lo.Li. Pharma International and Farmares.
Does Lo.Li. Pharma have an API?
No public API is recorded for Lo.Li. Pharma.
What industry is Lo.Li. Pharma in?
Lo.Li. Pharma's product category is Pharmaceutical Dietary Supplements and Medical Devices. Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 3254 and its SIC code is 2834.